Movatterモバイル変換

[0]ホーム

Jump to content

Oleclumab

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Oleclumab
Monoclonal antibody
Type	?
Source	Human
Target	5'-nucleotidase NT5E
Clinical data
Other names	MEDI9447
ATC code	none
Identifiers
CAS Number	1803176-05-7
ChemSpider	none
UNII	5CRY01URYQ
KEGG	D10963
Chemical and physical data
Formula	C₆₃₄₈H₉₈₂₆N₁₇₁₀O₁₉₉₈S₄₀
Molar mass	143350.81 g·mol⁻¹

Oleclumab (INN;^[1] development codeMEDI9447) is a human monoclonal antibody targeting the ectonucleotidaseCD73^[2] that was designed for the treatment ofpancreatic andcolorectal and other cancers.^[3]

This drug was developed byMedImmune/AstraZeneca.^[4]

References

[edit]

^World Health Organization (2016)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116"(PDF).WHO Drug Information.30 (4).
^Kowash RR, Akbay EA (2023)."Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer".Frontiers in Immunology.14 1130358.doi:10.3389/fimmu.2023.1130358.PMC 10079876.PMID 37033953.
^ClinicalTrial.gov for Oleclumab
^Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab,American Medical Association.

Thismonoclonal antibody–related article is astub. You can help Wikipedia byadding missing information.

Monoclonal antibodies for theimmune system

Immune system

Human	Immunosuppression:Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Nipocalimab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation:Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other:Bertilimumab Ontamalimab Zanolimumab Combination:Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive:Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab (+berahyaluronidase alfa) Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation:Dostarlimab Other:Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatorylesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Retrieved from "https://en.wikipedia.org/w/index.php?title=Oleclumab&oldid=1324061711"

Categories:

Hidden categories:

[8]ページ先頭